COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction — COLD-MI  

Myocardial Infarction, Acute Clinical Trial

Official title: COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction

Status Terminated

Clinical Trial Summary

This study evaluates the benefit of colchicine on induced denervation after myocardial infarction. Patients who have suffered a documented De Novo myocardial infarction and completed a revascularization procedure will receive either colchicine on top of standard therapy, compared to standard therapy alone (1:1 allocation ratio). Colchicine 1mg (or 0.5mg) will be initiated within 48h after percutaneous revascularization and prescribed for one month.

Clinical Trial Description

COLD-MI study aims to explore colchicine's impact on myocardial denervation following reperfused acute myocardial infarction. Acute myocardial infarction is the leading cause of heart failure (HF). It induces myocardial denervation predisposing to ventricular rhythm disorders and death. This denervation linked to infarction's size occurs by direct ischaemic mechanisms during the initial coronary occlusion (initially non-vascularised zone) and secondarily by cardiac remodelling in the context of the heart failure (HF). In usual practice, cardiac denervation which intensity is correlated with rhythm and mortality risks, can be evaluated by scintigraphy. In a murine reperfusion model of ischemia, the direct anti-inflammatory effect of colchicine reduces the size of the necrosis and improves post-ischemic remodeling. This suggests that colchicine may reduce myocardial denervation. ;

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction
• Myocardial Infarction, Acute

• NCT number: NCT04420624
• Study type: Interventional
• Source: University Hospital, Montpellier
• Status: Terminated
• Phase: Phase 2/Phase 3
• Start date: December 4, 2020
• Completion date: May 24, 2022